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Abstract
Purpose The expression of human epidermal growth factor
receptor-2 (HER2) receptors in cancers is correlated with a
poor prognosis. If assessed in vivo, it could be used for
selection of appropriate therapy for individual patients and
for monitoring of the tumor response to targeted therapies.
We have radiolabeled a HER2-binding Affibody molecule
with fluorine-18 for in vivo monitoring of the HER2 ex-
pression by positron emission tomography (PET).
Materials and methods The HER2-binding ZHER2:342–Cys
Affibody molecule was conjugated with N-2-(4-[
18F]fluoro-
benzamido)ethyl]maleimide([
18F]FBEM). The in vitro binding
of the resulting radioconjugate was characterized by receptor
saturation and competition assays. For in vivo studies, the
radioconjugate was injected into the tail vein of mice bearing
subcutaneousHER2-positiveorHER2-negativetumors.Some
of the mice were pre-treated with non-labeled ZHER2:342−Cys.
The animals were sacrificed at different times post-injection,
and the radioactivity in selected tissues was measured. PET
images were obtained using an animal PET scanner.
Results In vitro experiments indicated specific, high-affinity
binding to HER2. PET imaging revealed a high accumula-
tion of the radioactivity in the tumor as early as 20 min after
injection, with a plateau being reached after 60 min. These
results were confirmed by biodistribution studies demon-
strating that, as early as 1 h post-injection, the tumor to blood
concentration ratio was 7.5 and increased to 27 at 4 h. Pre-
saturation of the receptors with unlabeled ZHER2:342–Cys
lowered the accumulation of radioactivity in HER2-positive
tumors to the levels observed in HER2-negative ones.
Conclusion Our results suggest that the [
18F]FBEM-ZHER2:342
radioconjugate can be used to assess HER2 expression in vivo.
Keywords Breastcancer.Molecularimaging.HER2.
PET.F-18
Introduction
Progress in tumor biology has resulted in characterization of
specific cancer markers possessing prognostic and predictive
value. Among the most studied markers is the human
epidermal growth factor receptor-2 (HER2/neu/c-erbB-2), a
member of the epidermal growth factor receptor family of
tyrosine kinases (EGFR) [1, 2]. This 185-kDa transmem-
brane phosphoglycoprotein plays a key role in many cell-
ular processes, including cell growth, differentiation, cell
survival, and cell adhesion and migration. Whereas normal
epithelial cells do not express HER2 protein (or express a
very low level) on the cell surface, amplification of the
HER2/neu gene and/or overexpression of the protein have
been identified in 20–30% of invasive breast and lung
cancers, as well as in ovarian carcinomas and B-cell acute
lymphoblastic leukemia [3, 4]. The majority of the reports
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progression and decreased overall survival. The HER2-
positive status is associated with resistance of cancers to
hormone therapy and certain types of chemotherapy [5].
Therefore, the expression of HER2 receptors in cancers is
correlated with a poor prognosis [6].
Because the HER2 expression levels in distant metasta-
ses may be quite distinct from levels in the primary tumor
[7, 8], an assessment of the global expression of these
receptors on cancer cells in vivo is essential for adequate
diagnosis and selection of appropriate therapy.
Recently, significant advances have been made to
develop probes for targeting antigens commonly overex-
pressed in human cancer cells. Several monoclonal anti-
bodies and antibody fragments have already been approved
for clinical use [9], including a recombinant humanized
version of anti-HER2 monoclonal antibody trastuzumab
(Herceptin), which has shown significant clinical efficacy
in trials with HER2-overexpressing breast cancers [10]. The
success of trastuzumab was followed by the introduction of
other therapeutic antibodies targeting HER2 receptors, e.g.,
pertuzumab [11]. It has been reported that the outcome of
these therapies in individual patients depends on the HER2
status of the treated tumors [12].
Radiolabeled trastuzumab [13–16]o rF ( a b ′) fragments of
trastuzumab labeled with In-111 and Ga-68 have been used
for single-photon emission computed tomography (SPECT)
and positron emission tomography (PET) imaging, respective-
ly. However, antibodies are rather bulky proteins as compared
with the molecular probes typically used for PET imaging [17,
18], which make the tumor penetration and clearance from the
circulation rather slow, and this, in turn, considerably affects
imaging studies. Furthermore, trastuzumab-based tracers can-
not be used to monitor possible changes in HER2 expression
caused by treatment with this antibody because of the
competition of the imaging and therapeutic molecules for
binding to these receptors.
A promising alternative to antibodies as targeting agents
are Affibody molecules—highly stable proteins that are four
times smaller than single-chain antibody fragments (scFv)
and 20 times smaller than monoclonal antibodies [19]. The
cysteine-free Affibody molecules provide a strong frame-
work independent of disulfide bonds for its folding, and
their small size enables penetration into solid tumors and
rapid clearance from the bloodstream. Although the existing
library of Affibody molecules can be used to select binders
to different structures, in this work, we use the term in re-
ference to the HER2-binding Affibody molecules. They
constitute a highly suitable carrier for directing radioisotopes
or toxins to HER2-positive tumor cells because of specific
target binding and lack of specific non-receptor interactions,
suchastheFcreceptorbindingdisplayedbysomeantibodies.
It has been shown that radiolabeled Affibody molecules
display specific binding to HER2 receptors and rapid uptake
in tumor xenografts [20, 21]. Furthermore, the binding is
unaffected by pretreatment of the target tumor cells with
trastuzumab [22], indicating that radiolabeled Affibody
molecules and trastuzumab bind to distinct regions of the
extracellular domain of HER2. This observation suggests
that radiolabeled Affibody molecules can be used effec-
tively for monitoring of receptor expression in patients
undergoing treatment with trastuzumab.
PETimaging has been routinely used in the neurosciences
for in situ quantification of receptor expression [23, 24].
Delforge et al. [25] used PET for in vivo quantification of
cardiac β-adrenergic receptors and was able to obtain their
density maps. Recent studies showed that PET might also
serve as a useful imaging modality to measure growth fac-
tor receptor expression on tumor cells [26]. The global
assessment of receptor expression by PET will help prevent
false-negative results because of the heterogeneity of tumors
that cannot be fully represented by biopsy probes. This ap-
proach will permit the non-invasive identification of patients
that are suitable for targeted therapy designed against HER2-
positive tumors and will provide information about the
immediate response to therapeutic interventions, which can
then be adjusted for individual patients based on the actual
status of those receptors.
18F is routinely applied in clinical
oncology in the form of fluorodeoxyglucose (FDG), a Food
and Drug Administration-approved glucose analog. There-
fore, it is widely used and readily available.
This study is the first to describe the synthesis as well as in
vitro and in vivo characterization of a novel HER2-specific
[
18F]FBEM-ZHER2:342–Affibody molecule radioconjugate
that may allow the application of PET imaging to assess in
vivo HER2 expression.
Materials and methods
General
Unless otherwise specified, all reagents were analytical grade
and were obtained from commercial sources. The ZHER2:342–
Cys Affibody molecules were kindly provided by our
Cooperative Research and Development Agreement
(CRADA) partner in Sweden (Affibody AB; http://www.
affibody.com).
18F radionuclide was obtained from the NIH/
CC cyclotron facility from proton irradiation of O-18-enriched
water.Trastuzumab(Herceptin)waspurchasedfromGenentech,
San Francisco, CA, USA, as a lyophilized white powder and
reconstituted with the supplied solvent. Pentamethylbenzyl
(4-trimethylammonium) benzoate trifluoromethanesulfonate
was prepared as described previously [27].
Eur J Nucl Med Mol Imaging (2008) 35:1008–1018 1009Synthesis of N-(2-(4-[
18F]fluorobenzamido)ethyl)
maleimide ([
18F]FBEM)
[
18F]Fluorobenzoic acid was prepared as previously described
using a manual synthesis method [28]. Briefly, pentameth-
ylbenzyl (4-trimethylammonium) benzoate trifluorometha-
nesulfonate (3 mg, 6 µmol) was heated for 10 min in a
sealed V-vial with [
18F]fluoride (550 to 2,220 MBq) in the
presence of Kryptofix (2.2.2; 6 µmol) and K2CO3 (3 µmol)
in CH3CN (0.1 ml). The intermediate was treated with
trifluoroacetic acid (TFA) to provide 4-[
18F]fluorobenzoic
acid. The 4-[
18F]fluorobenzoic acid was treated with N-
(2-aminoethyl)maleimide (1.52 mg, 6 µmol), diethyl cyano-
phosphonate (1.3 mg, 8 µmol), and N,N-diisopropylethyl
amine (10 ml). The resulting solution was heated at 70°C
for 5 min. This solution was diluted with 150 µl water and
injected onto an high-performance liquid chromatography
(HPLC) column [Luna C-18 (Phenomenex), 10×250 mm,
20% CH3CN, 80% water, 5 ml/min]. The product eluting at
about 17 min wascollected, dilutedto about 20ml withwater
and trapped on a BondElut C-18 (500 mg). The product was
eluted from the column with CH2Cl2; the organic layer was
carefully separated from the small amount of water and
carefully evaporated into the bottom of a 1.5-ml Eppendorf
tube.
Conjugation of N-2-(4-[
18F]fluorobenzamido)ethyl]
maleimide with ZHER2:342−Cys
([
18F]FBEM-ZHER2:342–Affibody)
The isolated [
18F]FBEM (111–370 MBq) was dissolved in
10 µl of CH3CN. In the meantime, stock Affibody molecule
ZHER2:342–Cys (100 µg in 100 µl phosphate-buffered saline,
PBS; 12 nmol) was treated with 10 µl of 1 M dithiothreitol
(DTT) for 40 min at 37°C. The solution was then eluted in
0.25 ml fractions of 0.1 M NaOAc, 0.1% ascorbic acid,
pH 7, from a NAP-5 column (GE Healthcare Bio-Science
AB, Uppsala, Sweden; cut-off, 5 kDa). Fraction 4 (0.25 ml)
from this column was added to the solution of [
18F]FBEM.
This solution was incubated for 15–30 min at room tem-
perature and loaded onto a NAP-5 column. The NAP-5
column was eluted with 250 µl portions of PBS. The most
concentrated fraction containing the radiolabeled protein
(fraction 4) was collected and used for the biological experi-
ments. The radiochemical yield of
18F-labeled Affibody
conjugate using this un-optimized procedure was approxi-
mately 5% based on starting
18F-fluoride and uncorrected for
decay. The total procedure requires about 2 h.
Protein concentration of the labeled preparation was
determined by measuring UVabsorbance at 280 nm (Nano-
Drop Technologies, Wilmington, DE, USA) using the
conversion 1 AU=0.99 mg/ml.
HPLC analysis of [
18F]FBEM-ZHER2:342–Affibody
Analysis of the protein product was conducted using a Vydac
protein C-4 column (4.5×150 mm). Gradient elution was
employed (5–75% of 0.1% TFA in acetonitrile versus 0.1%
TFA in water over 15 min). [
18F]FBEM-ZHER2:342–Affibody
molecules were eluted at about 8 min.
Cell lines
Humanparentalbreast(SKBR-3,MCF7)andovarian(SKOV-
3) cancer cell lines that express different levels of HER2, as
well as a HER2-negative human glioblastoma cell line
(U251), were purchased from the American Type Culture
Collection (Rockville, MD, USA). The breast cancer cell line,
stably transfected with HER2 (MCF7/HER2–18), was kindly
provided by Dr. John W. Park, University of California, San
Francisco, CA, USA. The cells were cultured in DMEM/F12
medium (SKBR-3, SKOV-3, U251) or in DMEM (MCF7,
MCF7/HER2-18)supplementedwith10%(v/v) heat-inactivated
fetal bovine serum (GIBCO, Grand Island, NY, USA) and
penicillin/streptomycin(100U/mlofeach).Cellsweregrown
as a monolayer at 37°C in a humidified atmosphere contain-
ing 5% CO2. In the case of MCF7/HER2 transfectants, the
culture medium also contained 400 µg/ml Geneticin, G418
(GIBCO, Grand Island, NY, USA).
In vitro cell-binding assays
The in vitro binding characteristics of the [
18F]FBEM-
ZHER2:342–Affibody molecules were assessed using satura-
tion and displacement cell-binding assays. The day before
the experiments, cells were seeded in six-well plates at con-
centration of 2.5×10
5 cells per ml. For receptor saturation
analysis, the cells were incubated (4°C, 2 h) with increasing
concentrations (3.3–420 nM) of [
18F]FBEM-ZHER2:342–
Affibody alone or with additional 100-fold excess of non-
labeled Affibody molecules. Then, the incubation medium
was collected, and the cells were washed with cold PBS and
trypsinized, and the cell-associated radioactivity was mea-
sured using a γ-counter (1480 Wizard 3, Automatic Gamma
Counter, Perkin-Elmer, Waltham, MA, USA). The total non-
specific and specific binding were plotted against the total
molar concentration of added [
18F]FBEM-ZHER2:342–Affi-
body, and the data were analyzed by non-linear regression
using GraphPad Prism (GraphPad Software, San Diego, CA,
USA)
For the displacement assay, the cells were incubated with
216 nM of [
18F]FBEM-ZHER2:342–Affibody and increasing
concentrations (1.2 nM–120 µM) of non-labeled Affibody
molecules. The rest of the experimental procedures were
the same as those used for the saturation studies.
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that express different numbers of HER2 receptors. The ex-
periments were carried out at the same way as for saturation
analysis; however, in this case, only one concentration of
[
18F]FBEM-ZHER2–Affibody was chosen. In addition, some
wells were preincubated (30 min) with 100-fold excess
amount of unlabeled Affibody or trastuzumab (1 µg/ml).
Tumor model
Five- to 7-week-old female athymic nude mice were injected
subcutaneously with 1×10
7 of SKOV-3 or with 10
6 of
U251 cells suspended in Matrigel (BD Bioscience, San
Jose, CA, USA). Tumors were placed on the hind leg or on
the back. These locations were chosen to optimize the PET
images by placing thetumor wellaway from theradioactivity
in major body structures and reduce background radioactiv-
ity.U251andSKOV-3tumors(50–250mg)developedafter2
and 4–5 weeks, respectively. All animal studies were con-
ducted in accordance with the principles and procedures out-
lined in the National Institute of Health Guide for the Care
and Use of Animals on approved studies from the National
Institutes of Health Institutional Animal Care and Use
Committee.
Biodistribution studies
Athymic nude mice bearing SKOV-3 tumors were injected
with 1.8–2.2 MBq (1.6–2 µg, 100 µl) of [
18F]FBEM-ZHER2–
Affibody into the tail vein. Groups of three to six mice were
sacrificed, and their organs dissected 1, 2, 3, 4, and 6 h
post-injection. Then, blood, tumor, and major organs were
collected and weighed. The radioactivity in the tissues was
measured along with a standard of the injected dose using
γ-counter. The results were calculated as percentage
injected dose per gram of tissue (% ID/g).
Tostudythebloodkineticsandthestabilityof[
18F]FBEM-
ZHER2:342–Affibody in vivo, the blood was collected at
1–6 h post-injection in vials containing 30 µl heparin. The
samples were weighed, and the radioactivity was measured
by γ-counter. Then, the blood was centrifuged (10 min at
10,000×g) and fractions of plasma (200–300 µl) were sep-
arated on NAP-5 columns. The mean concentrations of
radioactivity in the blood (% ID/g) were plotted against time
after injection, and the curve was fitted by single exponential
decay. Similar procedure was used to analyze high molecular
weight (HMW)/low molecular weight (LMW) ratio of
radioactivity in the urine collected 60 min post-injection.
Toconfirmthe specificity of binding in vivo, one group of
animals bearing HER2-negative U251 tumors was injected
with the [
18F]FBEM-ZHER2:342–Affibody and another group
bearing HER2-positive SKOV-3 tumors was pre-injected
with 400 µg of non-labeled Affibody 45 min before the
[
18F]FBEM-ZHER2:342–Affibody was injected. Two hours
later, all animals were sacrificed, and their organs analyzed
as described above.
PET studies
Mice were anesthetized using isoflurane/O2 (1.5–5% v/v)
and injected with approximately 3.7–4.4 MBq (3.4–4 µg,
100 µl) of the [
18F]FBEM-ZHER2:342–Affibody via the tail
vein. PET scans were performed using the Advanced
Technology Laboratory Animal Scanner (ATLAS) PETscan-
ner [29]. Whole-body (1, 2, 3, 4, and 6 h; four bed positions,
each 15 min) and dynamic data acquisition (1 frame, 10 min,
up to 12 frames) were started about 2 min after radiotracer
injection and recorded with a 100–700 keV energy window.
Theimageswerereconstructedbyatwo-dimensionalordered-
subsets expectation maximum (2D-OSEM) algorithm, and no
correction was applied for attenuation or scatter. For each
scan, regions of interest were drawn over the tumor, normal
tissue, and major organs. The maximum radioactivity accu-
mulation within the tumor or organs was obtained from mean
pixel values within the multiple region of interest (ROI). The
results were calculated as a percentage injected dose per gram
(% ID/g) and standard uptake value (SUV). At the end of the
study, an
18F source of known activity was imaged to obtain
MBq of
18F per counts per second for the imaging system
(calibration factor). Then, every ROI (counts per second per
cubic centimeter) was multiplied by this factor and divided
by injected activity.
Results
Conjugation and labeling
Affibody molecule with a C-terminal cysteine provided func-
tionality for site-specific labeling using maleimide chemistry.
We prepared N-(2-(4-[
18F]fluorobenzamido)ethyl)maleimide
[
18F]FBEM using a similar method (Fig. 1) to that utilized
to prepare [
18F]fluoropaclitaxel [28]. An alternative synthe-
sis of [
18F]FBEM has been previously reported [26]. 4-[
18F]
Fluorobenzoic acid was obtained by reaction of pentame-
thylbenzyl 4-trimethylaniliniumbenzoate trifluoromethane-
sulfonate with [
18F]fluoride followed by cleavage of the
ester function with TFA. 2-Aminoethylmaleimide was cou-
pled to [
18F]fluorobenzoic acid using diethyl cyanophospho-
nate as the coupling reagent. [
18F]FBEM was obtained in
22.0±4.7% radiochemical yield (n=44, uncorrected). The
[
18F]FBEM was purified by HPLC and, because of the
complexity of the overall synthesis, was not commonly
evaluated for purity. However, in the limited number of
radiochemical purity assays of the isolated [
18F]FBEM, we
consistently observed values greater than 95%.
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fide on storage, treatment with DTT and removal of excess
DTT using a NAP-5 column was utilized. The reduced
protein was incubated with [
18F]FBEM for 15–30 min. The
labeled protein was isolated by elution through a NAP-5
column with PBS and obtained in 6.5±2.2% radiochemical
yield (based on starting [
18F]fluoride, n=26, uncorrected).
HPLC demonstrates the presence of a single radiolabeled
species. Protein staining of the polyacrylamide gel electro-
phoresis showed a mixture of monomeric and dimeric pro-
teins;however,greaterthan90%oftheradioactivitymigrated
with the 8-kDa protein band. The specific radioactivity of the
resulting radioconjugate was in the range 1–2.3 MBq/μga t
the end of radiochemical synthesis.
Binding specificity in vitro
Competition for binding between [
18F]FBEM-ZHER2:342–
Affibody and non-radioactive Affibody molecules demon-
strate that [
18F]FBEM-ZHER2:342–Affibody can be displaced
by increasing amounts of unlabeled molecules (Fig. 2a).
This provides evidence for receptor-mediated binding to
HER2-expressing cells. Saturation analysis shows a single
class of high-affinity binding sites that had a mean equi-
librium dissociation constant (KD) of 15 nM for the SKOV-3
cell line.Figure 2b shows the total non-specific and specific-
binding plotted against the total molar concentration of
added [
18F]FBEM-ZHER2:342–Affibody. Similar studies were
performed with the SKBR-3 cell line, which demonstrated
that the [
18F]FBEM-ZHER2:342–Affibody conjugate bound
with similar affinity (data not shown). Specificity of binding
was also tested using cell lines expressing different numbers
of HER2 receptors. As shown in Fig. 3, binding to HER2-
negative cells was comparable to that observed in experi-
ments in which addition of 100-fold excess of unlabeled
Affibody molecules almost completely blocked the HER2
receptors for [
18F]FBEM-ZHER2:342–Affibody binding. We
alsotestedwhetherpre-incubationwithtrastuzumabinterferes
with binding of [
18F]FBEM-ZHER2:342–Affibody. Radio-
labeled Affibody molecules and trastuzumab bound non-
competitively, which confirms that [
18F]FBEM-ZHER2:342–
Affibody and trastuzumab bind to different epitopes on the
extracellular domain of HER2.
Biodistribution studies
The results of the biodistribution studies are summarized in
Tables 1 and 2. Among the organs evaluated, the most pro-
minent [
18F]FBEM-ZHER2:342–Affibody uptake was found
in the kidneys, bone, and tumor. However, the radioactivity
in the kidneys decreased from 14% ID/g to 1.5% ID/g at,
respectively, 1 and 4 h post-injection because of excretion of
the tracer to the urinary bladder. All other tested organs
exhibited very low levels of tracer uptake over the entire
time course, which resulted in a significantly high tumor-
to-background tissue radioactivity accumulation ratio
(Table 2). It is noteworthy that the uptake of radioactivity
2 h post-injection was higher in the tumor than in any other
organ. This level remained steady until the 6-h time point.
The specificity of binding in vivo was evaluated in two
independent experiments. In each case, mice were sacrificed
2 h post-injection, and the radioactivity in the blood and
majororganswasmeasured.Asexpected,blockingtheHER2
receptors in mice bearing HER2-positive SKOV-3 tumors
Fig. 1 Synthetic route used for
labeling of the ZHER2:342–Cys
Affibody molecule with
18F.
DECP Diethyl cyanophospho-
nate, DIPEA N,N-
diisoproplyethylamine
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decrease of radioactivity in the tumor, as only tumors
expressed high numbers of HER2 receptors. In the blood
and the rest of organs examined, there was no significant
change because of pre-treatment with non-labeled molecules
(Fig. 4a). Receptor-mediated binding of radiotracer was
confirmed by successful blocking with non-labeled Affi-
body molecules.
The in vivo HER2-binding specificity was also tested
using a group of animals that were bearing HER2-negative
U251 tumors. The tumor-associated radioactivity in this
group was the same as that observed in those animals pre-
treatedwithanexcessofnon-labeledAffibody(Fig.4a). This
confirms that the [
18F]FBEM-ZHER2:342–Affibody accumu-
lation is HER2-dependent rather than a non-specific
trapping of proteins because of variations in the vasculari-
zation of the tumor tissue.
Pharmacokinetic studies
The mean radioactivity expressed as % ID/g in the blood
over time for the group of three to six mice after intravenous
administration of [
18F]FBEM-ZHER2:342–Affibody is shown
in Fig. 4b. The clearance from the blood system was rapid.
The radioactivity concentration was 2.7±0.06, 1.31±0.25,
and 0.28±0.07% ID/g at 30, 60, and 120 min post-injection,
respectively (n=3–6). The fitting of the kinetic curve with
exponential decay indicated that the elimination half-life of
the tracer in blood is 36 min. Mouse plasma was also evaluated
for metabolic stability of [
18F]FBEM-ZHER2:342–Affibody. To
distinguish radiolabeled Affibody (high molecular weight)
from small molecule metabolites (low molecular weight),
plasma samples were eluted through NAP-5 columns (5 kDa
cut-off) with PBS. Reference analysis of the [
18F]FBEM-
ZHER2:342–Affibody on the NAP5 column revealed 67% in the
HMW fraction. The majority of radioactivity from plasma
samples was associated with the HMW fractions, indicating
that the [
18F]FBEM-ZHER2:342–Affibody was present in the
blood at late time points (table insert, Fig. 4b). Relatively
low level of the radioactivity in the HMW fraction (<20%)
of the urine obtained at 60 min post-injection suggests that
most of the radioactivity present in the urine cannot be
attributable to radiolabeled protein.
PET imaging
Representative whole-body decay-corrected coronal images
wereobtained from mice bearing SKOV-3 tumors at different
time points after tracer injection (Fig. 5). These images
confirmed that the [
18F]FBEM-ZHER2:342–Affibody mole-
cules accumulate in the tumor. Tumor uptake was signifi-
cantly above the background as early as 20 min post-[
18F]
FBEM-ZHER2:342–Affibody injection. The liver and kidney
radioactivity was high only during the first hour because of
non-specific accumulation but then gradually dropped over
time. The prominent radioactivity accumulation in the
kidneys and urinary bladder suggests that the agent was
primarily cleared through the renal pathway.
Fig. 3 The binding of [
18F]FBEM-ZHER2:342–Affibody molecules to
cells with different levels of HER2 expression [cell line versus
normalized cell-associated radioactivity (%) and the effect of pre-
incubation with either Affibody molecules or trastuzumab on the
binding, n=3]. The standard errors were in the range 0.1 to 3.1%
Fig. 2 Characterization of HER2-specific binding. a Representative
results of competition-binding assay using SKOV-3 cells (log of
concentration of competitor compound versus percent of the maximum
specific binding of radiolabeled Affibody molecule). b Representative
results of saturation assay using SKOV-3 cells (concentration of
radiolabeled Affibody molecule versus concentration bound: NSB non-
specific binding obtained by saturation of the receptors with 100-fold
excess of non-labeled Affibody, TB total binding, and SB specific binding)
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Representative coronal images were selected at different time
points (Fig. 6, upper panels). Time–activity curves showed
high tumor activity accumulation (SUV = 2.4) as early as
20 min post-injection (Fig. 6, lower panel), which reached a
plateau by 40 min (SUV=3.15, 3.32, 3.43, 60, 90, and
120 min, respectively). Whereas the kidney’su p t a k ew a s
muchhigherthanthatoftumoronlyduringthefirsthour,very
rapid clearance was observed at later time points. The ideal
time point for monitoring tumors appears to be 1 h after
injection oftracer. Atthistimepoint tumor uptakereachedthe
maximum of accumulation according to high-contrast PET
images. The uptake observed in major organs also correlated
well with biodistribution studies (data not presented).
Discussion
AnaccurateassessmentofHER2expressioniscrucialforthe
selection of patients that may benefit from HER2-targeted
therapies. Currently, ex vivo techniques, such as immuno-
histochemistry and fluorescence in situ hybridization, are
used to estimate HER2 expression before recommending
HER2-tageted molecular therapies, of which the most
common is treatment with trastuzumab. However, these
screening approaches have significant limitations. New
methods are needed to allow for non-invasive or minimally
invasive evaluation of HER2 expression in vivo that can be
Table 2 Tumor/organ ratios for [
18F]FBEM-ZHER2:342 conjugate in
mice bearing SKOV-3 xenografts
Ratio 1 h 2 h 3 h 4 h
Tumor/blood 7.5±4.5 23±5.5 27±10.7 69±27
Tumor/kidney 0.7±±0.1 1.5±0.6 3±0.4 4±0.8
Tumor/bone 4.5±1.2 3±0.6 3±0.4 5±2.6
Tumor/muscle 21±4.7 106±56.8 116±24.7 311±167
Each data point represents an average±SD from n =3 –6
Table 1 Biodistribution of [
18F]FBEM-ZHER2:342–Affibody in mice bearing SKOV-3 xenografts
Organ % ID/g 1 h 2 h 3 h 4 h 6 h
Blood 1.31±0.75 0.28±0.04 0.25±0.09 0.09±0.03 0.16±0.08
Heart 0.93±0.22 0.14±0.02 0.07±0.01 0.05±0.02 0.06±0.01
Lungs 2.85±0.65 0.46±0.27 0.34±0.12 0.28±0.07 0.23±0.03
Kidney 14.08±0.05 4.17±1.41 2.36±0.11 1.53±0.80 1.43±0.29
Spleen 2.05±0.52 0.23±0.09 0.17±0.02 0.11±0.06 0.15±0.04
Liver 5.04±0.69 0.88±0.51 0.68±0.18 0.33±0.08 0.41±0.05
Pancreas 0.80±0.16 0.10±0.04 0.07±0.03 0.08±0.05 0.06±0.01
Tumor 9.73±1.91 6.36±1.26 6.95±0.93 6.22±1.25 6.80±0.01
Bone 2.15±0.40 2.07±0.37 2.27±0.27 1.28±0.64 0.60±0.04
Brain 0.08±0.01 0.02±0.01 0.02±0.01 0.01±0.01 0.02±0.01
Stomach 1.02±0.13 0.16±0.03 0.44±0.52 0.08±0.01 0.10±0.05
Sm. intestine 2.26±1.73 0.11±0.04 0.30±0.21 0.24±0.17 0.51±0.30
Muscle 0.46±0.05 0.06±0.02 0.06±0.01 0.02±0.01 0.05±0.01
Numbers represent mean uptake expressed in % ID/g ± SD (n=3–6).
Fig. 4 a The
[18F]FBEM-ZHER2:432–Affibody uptake 2 h post i.v.
injection in athymic nude mice bearing either HER2-positive SKOV-3
cells after pretreatment with or without non-radioactive Affibody or
HER2-negative U251 tumors (tissue type versus % ID/g tissue). Each
bar represents an average ± SD from n=3–6. b Blood kinetics of [
18F]
FBEM-ZHER2:342–Affibody. The squares represent % ID/g in the
blood with an exponential curve fit. Insert Average HMW fractions of
the plasma-associated radioactivity. Each point represents mean ± SD
(three to four mice)
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ment of global HER2 expression in both primary tumors and
distant metastasis. It is critical that these methods are also
capable of monitoring efficacy in response to targeted
therapy as measured by receptor levels on tumors. Thus,
the high resolution, sensitivity, and quantitative nature of
PET imaging offer an ideal alternative for assessing HER2
expression status. Radiotracers suitable for non-invasive
imaging of HER2 in vivo have been previously reported.
Robinson et al. developed and labeled with
124I a divalent
antibody (C6.5) fragment that effectively functions in the
imaging of HER2-positive tumors with PET. Moreover,
they validated a method for using a clinical PET/computed
tomography scanner to quantify tumor uptake [17]. The
p185
HER2 in xenografts could be distinguished by microPET
imaging using a different size and format of anti-p185
HER2
antibody fragments [30]. Smith-Jones et al. [16] used an
F(ab′) fragment of trastuzumab labeled with
111In and
68Ga
for SPECT and PET, respectively. However, the targeting
agent they used cannot be applied to monitor response to
trastuzumab, which is the current standard treatment for
HER2-positive breast cancer, because the probe will compete
for the same binding sites on HER2 receptors as non-labeled
trastuzumab. Therefore, a decrease in signalwill not correlate
with decreased expression.
TheAffibodymoleculesdescribedbyOrlovaetal.[31]a n d
Steffen et al. [32] offer a trastuzumab-compatible alternative
forHER2imaging. Using
125I-labeled ZHER2:342–Affibody mol-
ecules, tumor-specific accumulation of radioactivity was de-
monstrated, and a high-contrast visualization of HER2-positive
xenografts in mice was obtained 6 h post-injection.
More recently, promising results using the synthetic Affi-
bodymolecule
111In-DOTA-ZHER22:342-pep2 (DOTA, 1,4,7,10-
tetraazacyclododecane-N,N′,N″,N″′-tetraacetic acid) for
SPECT imaging were also reported by the same group [22].
In this study, biodistribution analysis revealed very high ac-
cumulation of the new tracer in tumor only 1 h post-injection
(23% ID/g). Consequently, high-contrast images as soon as
1 h post-injection using a Gamma Camera could be obtained.
The images obtained after treatment with 17-AAG (heat-
shock protein inhibitor) showed significant changes in the
observed signal. The same DOTA-modified constructs can
also be labeled with a positron emitter,
68Ga. Considering the
very efficient and straightforward labeling procedure and the
Fig. 5 An image of a mouse bearing SKOV-3 tumor located on the left shoulder and decay-corrected whole-body PET images of the same animal
obtained 1, 2, 3, and 4 h after i.v. injection of [
18F]FBEM-ZHER2–342–Affibody
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68Ga from commercially available
generators, this approach presents an attractive alternative
for PET imaging. However, we are not aware of any publi-
cation describing use of such conjugates.
Mume et al. [33] used maleimide chemistry for site-
specific radiboromination of (ZHER2:4)2-Cys. The resulting
conjugate was shown to bind specifically to the HER2-
expressing cell-line, SKOV-3, and the biodistribution studies
confirmed its ability to accumulate in SKOV-3 xenografts.
This preferential tumor binding combined with fast clearance
from normal organs resulted in high tumor-to-normal tissue
ratios at 4 h post-injection.
Cysteine-based chelators were incorporated by Tran et al.
[34] to ZHER2:342 for site specific labeling with
99mTc.
Again, the Affibody molecule-based radioconjugates, in this
case
99mTc-CGG-ZHER2:342, were shown to accumulate spe-
cifically in SKOV-3 xenografts and, because of rapid clear-
ance from the blood and other organs (except kidneys),
allowed clear images of tumors by Gamma-camera at 6 h
post-injection.
In this work, we have further demonstrated the feasibility
of using Affibody molecules to monitor HER2 expression.
By labeling ZHER2:342–Cys Affibody molecule with
18F, we
have created a new tracer that will allow the application of
a well-established PET methodology to quantify HER2 ex-
pression in vivo. The radionuclide chosen for the imaging
agent offers several distinct advantages: (1) broad avail-
ability, (2) high positron yield (almost 100%), (3) a half-life
(T1/2=109.7 min) that closely matches the relatively short
biological lifetime of Affibody molecules.
The cysteine residue on the C-terminal of ZHER2:342–Cys
allowed for the application of a well-defined labeling chem-
istry using [
18F]fluorine-labeled maleimide. Cai et al. [18]
described the radiosynthesis of N-(2-(4-[
18F]fluorobenza-
mido)ethyl)maleimide ([
18F]FBEM) and applied this mol-
ecule to the radiolabeling of an arginine–glycine–aspartic
acid peptide for imaging of αvβ3 integrin expression. We
developed an alternative synthesis of [
18F]FBEM that
employed the radiosynthesis of [
18F]fluorobenzoic acid
and then coupling to aminoethylmaleimide using diethyl-
cyanophosphate. This procedure was based on our previous
experience in the radiosynthesis of fluoropaclitaxel [28].
The preparation of the [
18F]FBEM was completed in a two-
pot, three-step reaction sequence and provided sufficient
product for coupling to the reduced ZHER2:342–Cys Affibody
molecule. The terminal cysteine caused the stock ZHER2–
Cys Affibody molecules to exist as a mixture of monomeric
and dimeric forms. Initially, we attempted to reduce the
disulfide bonds with Tris(2-carboxyethyl)phosphine (TCEP),
but we observed that the TCEP reacted with the limited
Fig. 6 Upper panels Transverse and coronal slices recorded during a dynamic study (acquisition time, 10 min each frame). Tumor is indicated by
the arrows. Lower panel Quantitative results of the image analysis
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18F]FBEM and precluded successful conjuga-
tion. We then adapted the procedure of Mume et al. [33] that
used DTT to reduce the protein and then removed the excess
DTT using a NAP-5 column before conjugation. These con-
ditions have proven quite reproducible for the preparation of
conjugated Affibody molecules.
The affinity observed when the radiotracer was bound to
HER2 receptors on SKOV-3 and SKBR-3 cells in vitro was
comparable to that of typical antibodies used clinically for
imaging and therapy (e.g., the reported affinity of trastuzu-
mab to HER2 is 5 nM) [35]. Our studies of the radiotracer
binding to tumor cells expressing different levels of HER2
showed that the total cell-associated radioactivity was (1)
correlated with the level of receptor expression, (2) reduced
by pre-treatment of the cells with non-labeled Affibody
molecules, and (3) was not affected by pre-treatment with
trastuzumab. Consequently, our radioconjugate might be
used to assess the level of receptor expression and possibly
to monitor the changes of its expression in tumors also in
patients treated with trastuzumab.
The results of our in vivo studies were very promising.
The calculated elimination half-life was about 36 min, which
definitely facilitated the imaging studies, whereas clearance
of antibody fragments is in the range of a few hours [36], and
trastuzumab requires about 25 days [37]. High accumula-
tion of the radioactivity in HER2-positive tumors as
compared with the background was observed as early as
20 min after injection as shown by PET imaging reached
the plateau after 40 min and remained at that level for the
duration of the experiments. For imaging purposes, this
ratio at such a short time post-injection is much better than
the previously published data with other HER2-targeting
agents that demonstrated much weaker tumor accumulation
and worse signal-to-background ratio [17, 31]. Four hours
later, the ratio increased to 69, which resulted in further
improvement of the contrast between tumor and the
surrounding tissues, as shown by the whole body scans
(Fig. 6, upper panels). By that time, only the bowel and the
urinary bladder indicated any accumulation of radioactivity.
These results were confirmed by the biodistribution studies
indicating that 1 h post-injection, the concentration of radio-
activity (% ID/g) in tumor was 7.5 times higher than that in
the blood. Two hours after injection, the tumor uptake was
higher than the uptake in any other organs, and levels
remained steady over the course of the study. Pretreatment
with non-radiolabeled Affibody molecules decreased the
tumor accumulation to the levels observed in HER2-negative
tumors, which was comparable to that found in the normal
organs, with the exception of the kidneys, where the uptake
was significantly higher. However, the radioactivity in the
kidneys decreased rapidly because of excretion of the tracer
to the urinary bladder. This rapid clearance of radioactivity
from the kidneys distinguishes our radioconjugate from other
Affibody-based radiotracers that (or their radioactive degra-
dation products) tend to accumulate in the kidneys. On the
otherhand,[
18F]FBEM-ZHER2:342 produced a higher level of
radioactivity in the bone as a result of possible dehaloga-
nation. Nevertheless, according to extrapolation of pre-
clinical biodistribution data using the Olinda simulation
package [38], several PET scans per year could be carried
out using the typical dose of 185 MBq without exceeding
the radiation doses to the patient that are allowed for routine
diagnostic purposes.
Conclusion
Our results suggest that the [
18F]FBEM-ZHER2–Affibody
radioconjugate described herein can be used to assess
HER2 expression in vivo by PET imaging and, therefore,
might be used to monitor possible changes of receptor
expression in response to therapeutic interventions. The
combination of a radionuclide commonly used in the clinic
and an Affibody molecule characterized by a relatively low
molecular weight (compared to antibodies or single chain
antibody fragments), high affinity to the target receptors,
and fast clearance from the blood and normal organs makes
it an optimal candidate for clinical applications.
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